Keyun Zhu

Keyun Zhu

Auto-generated profile, based on publicly available information

Keyun Zhu

Department of Thoracic Surgery , The Affiliated LiHuiLi Hospital of Ningbo University , Ningbo , 315040 , Zhejiang , China , nbu.edu.cn

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2026 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
KZKeyun Zhu
Keyun Zhu
MLMingrong Lin
Mingrong Lin
CLChengbin Lin
Chengbin Lin
THTao Hu
Tao Hu
ZCZhikai Cao
Zhikai Cao
JYJianjian Ying
Jianjian Ying
Background: Lung adenocarcinoma (LUAD) is a leading cause of cancer‐related mortality worldwide. The tumor microenvironment (TME) plays a pivotal role in LUAD progression, but the specific molecular mechanisms driving malignancy and immune evasion remain incompletely understood. Bone marrow stromal cell antigen 2 (BST2) has been implicated in other cancers, yet its functional role and therapeutic potential in LUAD require further elucidation. Methods: We integrated single‐cell RNA sequencing (scRNA‐seq) data from primary LUAD tissues and normal lung tissues with bulk RNA‐seq data from The Cancer Genome Atlas (TCGA)–LUAD and GEO cohorts. Malignant epithelial cells were identified using inferCNV analysis. Cellular trajectory and cell–cell communication analyses were systematically performed to delineate the malignant transformation process and its interactions with the TME. High‐dimensional weighted gene coexpression network analysis further identified key functional modules within malignant subpopulations. The oncogenic role of BST2 was comprehensively validated through differential expression analysis, survival analysis, gene set enrichment analysis (GSEA), and in vitro cellular assays, including RT‑qPCR, MTT, colony formation, Transwell invasion, and wound healing experiments. In addition, we employed the tumor immune dysfunction and exclusion (TIDE) algorithm to evaluate its association with immunotherapy response and performed drug screening via the Clue.io platform to explore its therapeutic potential. Results: scRNA‐seq analysis revealed significant heterogeneity in the TME and identified two distinct subpopulations of malignant epithelial cells. Trajectory analysis uncovered a specific lineage (Lineage 4) driving the normal‐to‐malignant transition, while cell communication analysis highlighted interactions between malignant cells and tumor‐associated macrophages (TAMs) mediated by MIF and APP signaling pathways. High‐dimensional weighted gene coexpression network analysis (hdWGCNA) identified a coexpression gene module (Module 1) specifically enriched in malignant subpopulations. By intersecting with a set of immunoregulatory genes, BST2 was ultimately determined as a key candidate oncogene. BST2 was significantly upregulated in malignant epithelial cells and TAMs, and its high expression was closely associated with poor patient prognosis. GSEA demonstrated that high BST2 expression was linked to the activation of crucial oncogenic pathways, including oxidative phosphorylation, Kras signaling, and epithelial–mesenchymal transition (EMT). In vitro validation further confirmed that BST2 knockdown suppressed LUAD cell proliferation, migration, and invasion. Furthermore, elevated BST2 expression was associated with reduced efficacy of immune checkpoint blockade (ICB) therapy. Conclusion: Our study unveils BST2 as a critical oncogene in LUAD, promoting tumor progression and influencing the TME, particularly via TAM recruitment. BST2 expression predicts patient prognosis and immunotherapy response, positioning it as a promising biomarker and therapeutic target.

1 January 2026 in Human Mutation
Verified
Journal Article
Open access
PDF file
THTao Hu
Tao Hu
WSWenbin Song
Wenbin Song
ZLZhaoyi Liu
Zhaoyi Liu
CSCangchang Shi
Cangchang Shi
XHXiaoyan Hu
Xiaoyan Hu
YLYingxi Li
Yingxi Li
Background: Colorectal cancer (CRC) is a common and lethal disease worldwide. The chromobox (CBX) protein family, integral to the Polycomb repressive complex 1 (PRC1), plays a crucial role in epigenetic regulation and the progression of cancer. The expression profiles, clinical importance, and roles of various CBX family members in CRC remain unclear, especially concerning nonepigenetic functions and roles in the tumor microenvironment. Methods: The transcriptional profiles of the entire CBX family, consisting of eight members, were systematically analyzed using multiple public databases. Genomic alterations, prognostic data, and GSEA identified CBX3 as an important oncogenic gene. To explore CBX3 expression patterns and their association with immune cell infiltration in the tumor microenvironment, single‐cell RNA sequencing was employed. Through experimental validation, cell proliferation, migration, apoptosis, and cell cycle analysis, the oncogenic role of CBX3 was confirmed. Experiments involving coimmunoprecipitation and immunofluorescence colocalization were performed to confirm protein–protein interactions and subcellular localization of the protein. The screening of the CMap was executed to find potential therapeutic compounds, sorted by CBX3 expression levels. Results: The integrated analysis revealed a complicated expression pattern of CBX family members in CRC, with notable increases in CBX2, CBX3, CBX4, and CBX8, whereas CBX6 and CBX7 were decreased in tumor tissues. The prognostic analysis revealed that higher levels of CBX3, CBX4, CBX6, CBX7, and CBX8 were connected to lower overall survival rates, whereas increased CBX5 expression was associated with improved prognosis. Among all members, CBX3 was noted for having the highest frequency of alterations and the most frequent copy number gain, establishing it as a leading oncogenic driver. Single‐cell analysis showed that CBX3 expression was predominantly found in malignant cells, and higher CBX3 levels were associated with increased infiltration of immunosuppressive regulatory T cells. CMap screening revealed that epidermal growth factor receptor (EGFR) inhibitors were the most significantly enriched compounds in the high CBX3 expression group. In vitro, reducing CBX3 expression decreased cell proliferation and migration, promoted apoptosis, and caused G2/M phase arrest in CRC cells. CBX3 interacts with EGFR, activating the PI3K/AKT signaling pathway and promoting epithelial–mesenchymal transition (EMT). Conclusion: CBX3 was identified as a crucial oncogenic factor in CRC, enhancing tumor development through its interaction with EGFR and activation of the PI3K/AKT signaling pathway. CBX3 could be an indicator for predicting patient outcomes and their response to EGFR inhibitor treatment, which serves as a promising biomarker and a potential therapeutic target to advance precision medicine.